ClearNote Health has achieved a significant regulatory milestone with the United Kingdom’s in vitro diagnostic (IVD) approval for its Avantect® Multi-Cancer Detection Test and Avantect® Ovarian Cancer Test. The approval marks a crucial step forward in expanding access to these advanced cancer detection tools across the UK, potentially transforming early diagnosis and improving patient outcomes. This latest development underscores ClearNote Health’s commitment to innovation in oncology diagnostics and signals a growing momentum in the global fight against cancer.
ClearNote Health Secures UK In Vitro Diagnostic Approval for Advanced Cancer Detection Tests
ClearNote Health has achieved a significant regulatory milestone with the UK’s in vitro diagnostic (IVD) approval for its cutting-edge cancer detection platforms, Avantect® Multi-Cancer Detection Test and Avantect® Ovarian Cancer Test. This approval enables the company to expand its footprint across the United Kingdom,…
—-
Author : Mia Garcia
Publish date : 2025-09-27 14:39:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8
